CliffBio
small molecule

RYKINDO

RISPERIDONE

Loss of exclusivityApril 2032latest FDA-listed patent expiry
CompanySHANDONG LUYE PHARMACEUTICAL CO LTD

Drug detail

Brand nameRYKINDO
Active ingredientRISPERIDONE
Strength12.5MG
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJanuary 2023
Marketing statusDISCN

Listed patents

PatentExpiresType
10406161April 2032product
10098882April 2032product
9532991April 2032product
9446135April 2032product
11110094April 2032product

More from SHANDONG LUYE PHARMACEUTICAL CO LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RYKINDO patent cliff — loss of exclusivity April 2032 | CliffBio